CVM

CEL-SCI Corporation (CVM) - 10-Q Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation (CEL-SCI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended March 31, 2026
Business Overview: CEL-SCI is a late clinical-stage biotechnology company focused on developing Multikine, an investigational immunotherapy for head and neck cancer, and L.E.A.P.S. technology for rheumatoid arthritis. The company has not generated any revenue to date and relies on capital raises to fund operations.

Key Financial Metrics

Debt and Liquidity: The company holds significant finance lease obligations totaling approximately $6.8 million ($2.4 million current). Cash balances decreased by approximately $9.1 million during the period, primarily due to operating losses and lease payments.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $2.7 million (20%) compared to the prior year period, driven by reduced operating expenses.
• Operating Expenses: Total operating expenses declined from $13.3 million to $10.7 million.
  • R&D Expenses: Decreased by $1.0 million (12%), primarily due to lower clinical trial costs and supplies.
  • G&A Expenses: Decreased by $1.6 million (33%), largely attributed to a $1.1 million reduction in public relations costs.
• Cash Position: Cash and cash equivalents dropped from $10.95 million at the start of the period to $1.89 million at period end, a decrease of $9.06 million.
• Share Count: Weighted average shares outstanding increased significantly to 8.08 million (from 2.49 million in the prior year) due to a 30-for-1 reverse stock split effective May 2025 and subsequent issuances.

Outlook, Risks, and Management Commentary

Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional capital to fund the confirmatory registration study for Multikine.

Capital Needs: The estimated cost for the confirmatory registration study is $30-$35 million. The company plans to raise additional capital through corporate partnerships, debt, or equity financings. There is no assurance that funds will be available on acceptable terms.

Clinical Progress:

• Multikine: Phase III data showed a 73% 5-year survival rate in the target population (low PD-L1, no lymph node involvement) versus 45% for the control group. The company is preparing for a 212-patient confirmatory registration study.
• Regulatory: The FDA has indicated the company may move forward with the confirmatory study. A Breakthrough Medicine Designation application was filed in Saudi Arabia in August 2025.

Subsequent Events: On May 13, 2026, the company sold 6,000,000 shares of common stock at $1.20 per share for gross proceeds of approximately $7.2 million. Additionally, the CEO and related trusts purchased restricted stock totaling approximately $479,000 in value.

Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses previously disclosed in the 2025 10-K.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $7.2 million raised in May 2026 against the estimated $30-$35 million cost of the confirmatory study and ongoing operating burn rate.
• Going Concern Status: Review the latest filings for updates on the "substantial doubt" disclosure and any new financing agreements.
• Reverse Stock Split Impact: Confirm the adjusted share count and per-share metrics reflect the 30-for-1 reverse split effective May 2025.
• Lease Obligations: Assess the impact of the $6.8 million in finance lease liabilities on future cash flow requirements.
• Regulatory Timeline: Monitor the enrollment status of the 212-patient confirmatory study and any FDA feedback on the study design.